Last reviewed · How we verify
Oral Anti Diabetics (OAD)
Oral Anti Diabetics (OAD) is a Oral Anti-Diabetic Agents (multiple classes) Small molecule drug developed by Sanofi. It is currently FDA-approved for Type 2 diabetes mellitus.
Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.
Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Oral Anti Diabetics (OAD) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Oral Anti-Diabetic Agents (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
OADs encompass multiple drug classes (sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, and others) that work through distinct pathways to reduce hyperglycemia. Sanofi manufactures several OAD products across these categories, each targeting different aspects of glucose homeostasis in type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (metformin-associated)
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus (PHASE2)
- A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (PHASE2)
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient (PHASE4)
- A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Anti Diabetics (OAD) CI brief — competitive landscape report
- Oral Anti Diabetics (OAD) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Oral Anti Diabetics (OAD)
What is Oral Anti Diabetics (OAD)?
How does Oral Anti Diabetics (OAD) work?
What is Oral Anti Diabetics (OAD) used for?
Who makes Oral Anti Diabetics (OAD)?
What drug class is Oral Anti Diabetics (OAD) in?
What development phase is Oral Anti Diabetics (OAD) in?
What are the side effects of Oral Anti Diabetics (OAD)?
Related
- Drug class: All Oral Anti-Diabetic Agents (multiple classes) drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus